EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
| ChEBI ID | CHEBI:6887 |
| ChEBI Name | methylphenidate |
| Stars | |
| Definition | A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy. |
| Last Modified | 22 February 2017 |
| Formula | C14H19NO2 |
| Net Charge | 0 |
| Average Mass | 233.307 |
| Monoisotopic Mass | 233.14158 |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Biological Roles: | analgesic An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms. immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. sympathomimetic agent A drug that mimics the effects of stimulating postganglionic adrenergic sympathetic nerves. Included in this class are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. adrenergic uptake inhibitor Adrenergic uptake inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. dopamine uptake inhibitor A dopaminergic agent that blocks the transport of dopamine into axon terminals or into storage vesicles within terminals. Most of the adrenergic uptake inhibitors also inhibit dopamine uptake. adrenergic agent Any agent that acts on an adrenergic receptor or affects the life cycle of an adrenergic transmitter. |
| Applications: | neuroprotective agent Any compound that can be used for the treatment of neurodegenerative disorders. analgesic An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms. antineoplastic agent A substance that inhibits or prevents the proliferation of neoplasms. antidepressant Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. central nervous system stimulant Any drug that enhances the activity of the central nervous system. immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. antipsychotic agent Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. vasoconstrictor agent Drug used to cause constriction of the blood vessels. psychotropic drug A loosely defined grouping of drugs that have effects on psychological function. sympathomimetic agent A drug that mimics the effects of stimulating postganglionic adrenergic sympathetic nerves. Included in this class are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. anti-anaemic agent A compound which increases either the number of red cells or the amount of haemoglobin in the blood. antiparkinson drug A drug used in the treatment of Parkinson's disease. adrenergic uptake inhibitor Adrenergic uptake inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. dopamine uptake inhibitor A dopaminergic agent that blocks the transport of dopamine into axon terminals or into storage vesicles within terminals. Most of the adrenergic uptake inhibitors also inhibit dopamine uptake. adrenergic agent Any agent that acts on an adrenergic receptor or affects the life cycle of an adrenergic transmitter. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| methylphenidate (CHEBI:6887) has part dexmethylphenidate (CHEBI:51860) |
| methylphenidate (CHEBI:6887) has part methyl (S)-phenyl[(S)-piperidin-2-yl]acetate (CHEBI:51857) |
| methylphenidate (CHEBI:6887) has role adrenergic agent (CHEBI:37962) |
| methylphenidate (CHEBI:6887) has role adrenergic uptake inhibitor (CHEBI:35640) |
| methylphenidate (CHEBI:6887) has role analgesic (CHEBI:35480) |
| methylphenidate (CHEBI:6887) has role anti-anaemic agent (CHEBI:75835) |
| methylphenidate (CHEBI:6887) has role antidepressant (CHEBI:35469) |
| methylphenidate (CHEBI:6887) has role antineoplastic agent (CHEBI:35610) |
| methylphenidate (CHEBI:6887) has role antiparkinson drug (CHEBI:48407) |
| methylphenidate (CHEBI:6887) has role antipsychotic agent (CHEBI:35476) |
| methylphenidate (CHEBI:6887) has role central nervous system stimulant (CHEBI:35337) |
| methylphenidate (CHEBI:6887) has role dopamine uptake inhibitor (CHEBI:51039) |
| methylphenidate (CHEBI:6887) has role immunosuppressive agent (CHEBI:35705) |
| methylphenidate (CHEBI:6887) has role neuroprotective agent (CHEBI:63726) |
| methylphenidate (CHEBI:6887) has role psychotropic drug (CHEBI:35471) |
| methylphenidate (CHEBI:6887) has role sympathomimetic agent (CHEBI:35524) |
| methylphenidate (CHEBI:6887) has role vasoconstrictor agent (CHEBI:50514) |
| methylphenidate (CHEBI:6887) is a racemate (CHEBI:60911) |
| methylphenidate (CHEBI:6887) is conjugate base of methylphenidate(1+) (CHEBI:51856) |
| Incoming Relation(s) |
| methylphenidate(1+) (CHEBI:51856) is conjugate acid of methylphenidate (CHEBI:6887) |
| IUPAC Name |
|---|
| rac-methyl (2R)-phenyl[(2R)-piperidin-2-yl]acetate |
| INNs | Source |
|---|---|
| methylphenidate | KEGG DRUG |
| méthylphénidate | WHO MedNet |
| methylphenidatum | ChemIDplus |
| metilfenidato | ChemIDplus |
| Synonyms | Source |
|---|---|
| dl-threo-methylphenidate | ChemIDplus |
| rac-threo-methyl α-phenyl-α-(2-piperidyl)acetate | ChEBI |
| rac-threo-α-phenyl-2-piperidineacetic acid methyl ester | ChEBI |
| threo-(±)-methylphenidate | ChemIDplus |
| methyl rac-threo-phenidylacetate | ChEBI |
| methyl rac-threo-α-phenyl-α-2-piperidinylacetate | ChEBI |
| Brand Names | Source |
|---|---|
| Cotempla xr-odt | ChEMBL |
| Daytrana | KEGG DRUG |
| Manual Xrefs | Databases |
|---|---|
| C07196 | KEGG COMPOUND |
| D04999 | KEGG DRUG |
| DB00422 | DrugBank |
| HMDB0014566 | HMDB |
| Methylphenidate | Wikipedia |
| US2507631 | Patent |
| US2957880 | Patent |
| Registry Numbers | Sources |
|---|---|
| Reaxys:200061 | Reaxys |
| CAS:113-45-1 | KEGG COMPOUND |
| CAS:113-45-1 | NIST Chemistry WebBook |
| CAS:20748-11-2 | ChemIDplus |
| Citations |
|---|